Document Type : Original Article
Authors
- . Bahman Salehi 1
- . Abolfazl Mohammadbeigi 2
- . Hamid Sheykholeslam 3
- . Esmail Moshiri 4
- . Fatemeh Dorreh 5
1 Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran
2 Department of Epidemiology and Biostatistics, Neurology and Neuroscience Research Center, Qom University of Medical Sciences, Qom, Iran
3 Department of Pediatric, Iran University of Medical Sciences, Tehran, Iran
4 Department of Anesthesiology, Arak University of Medical Sciences, Arak, Iran
5 Department of Pediatric, Arak University of Medical Sciences, Arak, Iran
Abstract
Objective: The aim of this study is to evaluate the effect of zinc and omega‑3 supplements as
adjunctive drugs in the treatment of attention‑deficit/hyperactivity disorder (ADHD) of children.
Methods: This study is a randomized, double‑blind clinical trial conducted on 150
children aged 6–15 years old that diagnosed as new cases of ADHD. Study subjects
were evaluated for 8 weeks. Besides of drug of choice (methylphenidate) for the ADHD,
patients received placebo in the control group (n = 50), zinc sulfate in second group
(n = 50), and omega‑3 (n = 50) in third group. Clinical improvement was checking
by Conners’ Parent and Teacher Rating Scales before and in 2nd, 4th, and 8th week of
treatment. Results were analyzed with SPSS version 16 software.
Findings: In this study, mean scores of Conners’ scale showed significant improvement
during treatment in the zinc group compared to control group in children that affected
to attention‑deficit disorder subtype of ADHD (P = 0.02). Moreover, in omega‑3 group,
better clinical response was seen than other groups (P < 0.05). However, there was no
significant difference between omega‑3 group compared to placebo group in the mean
scores of Conners’ scale (P = 0.89).
Conclusion: Zinc supplementation accompanied by the main treatment significantly
improves symptom of attention‑deficit disorder subtype of ADHD. However, omega‑3
supplementation was superior to zinc and placebo in the clinical improvement of ADHD.
Keywords
Stanton BF, Geme III JW, Schor NF, Behrman RE. Nelson
Textbook of pediatrics. 19th ed. Philadelphia: WB Saunders; 2011.
2. Krull KR, Augustyn M, Torchia MM. Attention deficit
hyperactivity disorder in children and adolescents:
Epidemiology and pathogenesis. UpToDate. Available
from: http://www.uptodate.com/contents/attention-deficithyperactivity-disorder-in-children-and-adolescentstreatment-with-medications. [Last Updated on 2015 Oct 13].
3. Greenbaum LA. Micronutrient Mineral Deficiencies. Nelson
Textbook of Pediatrics. 18th ed. Philadelphia: Saunders; 2007.
4. Stettler N, Bhatia J, Parish A, Stallings V. Feeding healthy
infants, children, and adolescents. Nelson Textbook of
Pediatrics. 19th ed. Philadelphia, PA: Elsevier Saunders; 2011.
5. Busch B. Polyunsaturated fatty acid supplementation for
ADHD? Fishy, fascinating, and far from clear. J Dev Behav
Pediatr 2007;28:139‑44.
6. Abrams S. Zinc deficiency and supplementation in children
and adolescents. UpToDate; 2007. URL: http://www.uptodate.
com/contents/zinc-deficiency-and-supplementation-inchildren-and-adolescents [Last updated on 2014 Jul 24].
7. Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate
as an adjunct to methylphenidate for the treatment of attention
deficit hyperactivity disorder in children: A double blind and
randomized trial. BMC Psychiatry 2004;4:9.
8. Bilici M, Yildirim F, Kandil S, Bekaroglu M, Yildirmis S, Deger O, et al. Double‑blind, placebo‑controlled study of
zinc sulfate in the treatment of attention deficit hyperactivity
disorder. Prog Neuropsychopharmacol Biol Psychiatry
2004;28:181‑90.
9. Dodig‑Curkovic K, Dovhanj J, Curkovic M, Dodig‑Radic J,
Degmecic D. The role of zinc in the treatment of hyperactivity
disorder in children. Acta Med Croatica 2009;63:307‑13.
10. Arnold LE, Bozzolo H, Hollway J, Cook A, DiSilvestro RA,
Bozzolo DR, et al. Serum zinc correlates with parent‑ and teacher‑
rated inattention in children with attention‑deficit/hyperactivity
disorder. J Child Adolesc Psychopharmacol 2005;15:628‑36.
11. Bélanger SA, Vanasse M, Spahis S, Sylvestre MP, Lippé S,
L’heureux F, et al. Omega‑3 fatty acid treatment of children
with attention‑deficit hyperactivity disorder: A randomized,
double‑blind, placebo‑controlled study. Paediatr Child Health
2009;14:89‑98.
12. Antalis CJ, Stevens LJ, Campbell M, Pazdro R, Ericson K,
Burgess JR. Omega‑3 fatty acid status in attention‑deficit/
hyperactivity disorder. Prostaglandins Leukot Essent Fatty
Acids 2006;75:299‑308.
13. Schmidt S, Stahl F, Mutz KO, Scheper T, Hahn A, Schuchardt JP.
Transcriptome‑based identification of antioxidative gene
expression after fish oil supplementation in normo‑and
dyslipidemic men. Nutr Metab 2012;9:7075‑9.
14. Toplak ME, Pitch A, Flora DB, Iwenofu L, Ghelani K, Jain U,
et al. The unity and diversity of inattention and hyperactivity/
impulsivity in ADHD: Evidence for a general factor with
separable dimensions. J Abnorm Child Psychol 2009;37:1137‑50.
15. Lepping P, Huber M. Role of zinc in the pathogenesis of
attention‑deficit hyperactivity disorder: Implications for
research and treatment. CNS Drugs 2010;24:721‑8.
16. Yorbik O, Ozdag MF, Olgun A, Senol MG, Bek S,
Akman S. Potential effects of zinc on information processing
in boys with attention deficit hyperactivity disorder. Prog
Neuropsychopharmacol Biol Psychiatry 2008;32:662‑7.
17. Oner O, Oner P, Bozkurt OH, Odabas E, Keser N, Karadag H,
et al. Effects of zinc and ferritin levels on parent and teacher
reported symptom scores in attention deficit hyperactivity
disorder. Child Psychiatry Hum Dev 2010;41:441-7.
18. Huss M, Völp A, Stauss-Grabo M. Supplementation of
polyunsaturated fatty acids, magnesium and zinc in children
seeking medical advice for attention-deficit/hyperactivity
problems – An observational cohort study. Lipids Health Dis
2010;9:105.
19. Sinn N. Polyunsaturated fatty acid supplementation for ADHD
symptoms: Response to commentary. J Dev Behav Pediatr
2007;28:262-3.
20. Rojas NL, Chan E. Old and new controversies in the alternative
treatment of attention-deficit hyperactivity disorder. Ment
Retard Dev Disabil Res Rev 2005;11:116-30.
)